# Quad-Agonist GLP Drugs for Severe Obesity: Future Perspectives

Canonical source: https://retacompare.com/research/quad-agonist-glp-drugs-for-severe-obesity-bmi-40

Therapeutic Applications · 2026-05-02


    As the field of obesity treatment evolves, quad-agonist peptides targeting multiple receptors may offer new therapeutic avenues for patients with severe obesity. These compounds, currently in early development, aim to enhance metabolic regulation beyond existing therapies.

 The big picture

With the recent advancements in obesity pharmacotherapy, particularly following the emergence of dual agonists like Tirzepatide and the ongoing Phase 3 trials of the triple agonist Retatrutide, researchers are now exploring the potential of quad-agonist drugs. These next-generation therapies could target multiple pathways to improve weight loss and metabolic health, particularly for individuals with a body mass index (BMI) of 40 or greater, classified as severe obesity. The current landscape includes various dual and mono-agonists, but the promise of quad-agonists lies in their ability to synergistically activate several hormonal pathways, potentially leading to enhanced efficacy.

 How it works

Quad-agonists are designed to activate four distinct receptors involved in metabolic regulation. While specific compounds are still in preclinical or early clinical stages, the theoretical framework suggests targeting receptors such as GLP-1, GIP, glucagon, and potentially additional metabolic regulators. By engaging multiple pathways, these drugs aim to improve appetite regulation, enhance energy expenditure, and promote better glycemic control. This multifaceted approach is hypothesized to yield superior outcomes compared to existing therapies, which primarily focus on singular or dual mechanisms.

 Key points at a glance

Quad-agonists are in early development stages, focusing on severe obesity treatment.

Current therapies include dual agonists like Tirzepatide and triple agonists like Retatrutide.

Quad-agonists may target GLP-1, GIP, glucagon, and other receptors.

Potential benefits include improved appetite control and metabolic regulation.

No quad-agonist or penta-agonist drugs are currently approved.

Research is ongoing to determine optimal receptor combinations and dosing strategies.

Companies like Hanmi and Amgen are exploring quad-agonist candidates.

 Where this fits in the pipeline

Currently, several companies are investigating quad-agonist peptides, including Hanmi's HM15275 and Amgen's MariTide. These programs are in the early stages of clinical development, with limited publicly disclosed data on efficacy and safety. The anticipated timeline for clinical trials remains uncertain, but early results are expected to inform the feasibility of quad-agonists in treating severe obesity. As this area of research evolves, it will be crucial to monitor the progress of these compounds through clinical trials to assess their therapeutic potential.

 What it could mean for patients

If successful, quad-agonist therapies could represent a significant advancement in the management of severe obesity. By engaging multiple pathways, these drugs may offer a more effective means of achieving sustained weight loss and improving metabolic health. However, the clinical impact remains speculative until rigorous trials validate their safety and efficacy. For patients struggling with severe obesity, the introduction of quad-agonists could provide new hope for achieving long-term weight management and associated health benefits.

 Open questions and what we don't yet know

Despite the promising potential of quad-agonists, several questions remain unanswered. Key concerns include the optimal receptor combinations for efficacy, potential side effects, and the long-term safety profile of these compounds. Additionally, regulatory hurdles may pose challenges in the approval process, as the field still lacks established guidelines for quad-agonist therapies. Researchers will need to address these gaps to ensure safe and effective treatment options for patients with severe obesity.

 Bottom line

The exploration of quad-agonist peptides represents a forward-looking approach to treating severe obesity, with the potential to enhance metabolic regulation significantly. While still in early development, these compounds may offer new therapeutic avenues for patients in the future.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources